About This Fund
Omega Fund VIII is the eighth flagship investment vehicle of Boston-based Omega Funds, closed in July 2025 with $647 million in capital commitments—surpassing its initial target of $600 million thanks to strong support from both new and returning investors. Building upon Omega’s proven track record, Fund VIII continues to focus on early through later-stage life-sciences companies developing transformative therapeutics and platforms. The fund targets opportunities in oncology, immunology, rare diseases, medical devices, and precision medicine—therapeutic areas where prior Omega-backed firms have brought 52 products to market and delivered 50 exits via M&A plus 47 public listings. The fund maintains Omega’s dual-market investment strategy, supporting management teams in both the United States and Europe through company creation, early venture financings, and later-stage rounds. With its established network and seasoned operational expertise, Omega seeks to back breakthrough solutions addressing severe unmet medical needs, leveraging capital plus strategic guidance to shepherd companies from clinical milestones to commercial adoption and exit.